trending Market Intelligence /marketintelligence/en/news-insights/trending/Rk6uLYZOgxzfL8VhLaP8pw2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

China plans to create adjuvant drug list, limit sales


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Climate Credit Analytics: Linking climate scenarios to financial impacts


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

China plans to create adjuvant drug list, limit sales

China's National Health Commission is planning to create a national adjuvant drug list combined with regulatory guidelines to curb their use, according to a notice by the regulator.

Adjuvant drugs are treatments applied to initial therapies as supplements. The state regulator will outline a national adjuvant drug list after provincial governments submit their lists of the top 20 best sold adjuvant drugs in their regions. The provincial regulators are asked to submit their lists by Dec. 31.

Provincial governments will also come up with their own list of adjuvant drugs within 10 workdays after the state regulator unveils the national list.

The state health regulator also plans to amend the national list more than once every year.

The state regulator said in the notice that tightening regulations on the use of adjuvant drugs is necessary to curb growing medical expenses at public hospitals.